1. Home
  2. LBTYK vs ACAD Comparison

LBTYK vs ACAD Comparison

Compare LBTYK & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Liberty Global Ltd. Class C

LBTYK

Liberty Global Ltd. Class C

HOLD

Current Price

$11.23

Market Cap

3.9B

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$22.73

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LBTYK
ACAD
Founded
2004
1993
Country
Bermuda
United States
Employees
6636
N/A
Industry
Cable & Other Pay Television Services
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
3.8B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
LBTYK
ACAD
Price
$11.23
$22.73
Analyst Decision
Buy
Analyst Count
0
22
Target Price
N/A
$30.55
AVG Volume (30 Days)
1.6M
1.4M
Earning Date
02-18-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.12
EPS
N/A
2.30
Revenue
N/A
$726,437,000.00
Revenue This Year
$15.41
$18.80
Revenue Next Year
$3.03
$11.70
P/E Ratio
N/A
$9.71
Revenue Growth
N/A
40.45
52 Week Low
$9.21
$14.18
52 Week High
$13.12
$28.35

Technical Indicators

Market Signals
Indicator
LBTYK
ACAD
Relative Strength Index (RSI) 36.36 56.45
Support Level $10.59 $19.87
Resistance Level $11.51 $22.97
Average True Range (ATR) 0.33 0.65
MACD -0.09 0.11
Stochastic Oscillator 6.40 97.81

Price Performance

Historical Comparison
LBTYK
ACAD

About LBTYK Liberty Global Ltd. Class C

Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: